Overview
Recursion uses automated laboratories and machine-learning models to identify drug candidates, and earns revenue mainly from discovery partnerships with large pharmaceutical companies. Revenue in 2025 was US$74.7 million[36]. The company is based in Salt Lake City, Utah[36]. It combined with Exscientia, another AI drug-discovery company, in November 2024, and its 2025 filing reflects the integration and disposals of some Exscientia assets[36]. Recursion’s value rests mainly on its clinical pipeline rather than on current revenue, so results depend on trial outcomes that are uncertain and slow to arrive. The Exscientia combination joined two of the earliest AI-first drug-discovery companies in one listed entity.
Appears in
Recursion Pharmaceuticals alternatives and competitors
Alternatives to Recursion Pharmaceuticals: companies ranked in the same lists.
- NVIDIA
Scale AI
Pony AI
WhiteFiber- MiniMax
Rezolve AI
Nscale
Kodiak AI
Aurora Innovation
Figure AI
Crusoe
Mistral AI
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.